**American Society for Blood and Marrow Transplantation (ASBMT)**

**Pharmacy Special Interest Group (SIG)**

**Excellence in Advocacy Award**

**Nomination Deadline: September 30, 2018**

The **Excellence in Advocacy Award** will be awarded to an ASBMT Pharmacy SIG member who has made a significant impact to the field of pharmacy in hematopoietic cell transplantation (HCT) through patient and/or practice advocacy. It will recognize an individual that has displayed a commitment to advancing the practice of HCT to improve the delivery of patient care, while incorporating and promoting the role of the pharmacist in the management of HCT patients. Examples of such advocacy may include, but are not limited to:

* Development of innovative practice models to improve patient care in the HCT or hematology/oncology setting
* Legislative lobbying for expanded scope of practice
* Impactful research relating to the value and impact of pharmacists in the HCT or hematology/oncology setting
* A superior dedication to the care of HCT patients which may include direct clinical care, access to care, etc.

The recipient of this award will receive a recognition plaque to be presented at the annual BMT Pharmacist Conference held in conjunction with Transplantation and Cellular Therapy (TCT) Meeting of ASBMT and CIBMTR and discounted meeting registration fee.

Eligibility: Nominees must be current members of the ASBMT Pharmacy SIG at the time of nomination submission. Self-nominations will be accepted.

Please email the completed **nomination form and a copy of the nominee’s CV** to:

Alex Shillingburg, PharmD, BCOP

Chair, ASBMT Pharmacy SIG Membership & Awards Working Committee

Email: alex.shillingburg@atriumhealth.org

**ASBMT Pharmacy SIG Excellence in Advocacy Award**

 **Nomination Form**

**Nominating Party Information**

|  |  |
| --- | --- |
| Name: |  |
| Affiliation: |  |
| Address: |  |
| Phone Number: |  |
| Fax Number: |  |
| E-mail: |  |

**Nominee’s Information**

|  |  |
| --- | --- |
| Name: |  |
| Affiliation: |  |
| Address: |  |
| Phone Number: |  |
| Fax Number: |  |
| E-mail: |  |

Please provide detailed information on how the nominee has contributed to the following. We recognize that advocacy efforts may not include activity in all of the following categories. Thus, it is appropriate to comment only on items that are applicable for the nominee (use separate page if necessary):

1. **Developed an innovative practice model and/or initiative that improves the delivery of patient care.**

Examples of these activities may include, but are not limited to, development/implementation of new services at the same or new/different institutions; enhancement of existing services or care models; implementation of innovative strategies for patient education; development/implementation of cost-savings initiatives; initiatives for quality improvement; creating and/or maximizing collaborative practice through a CPA or other formal credential (e.g. CPP).

1. **Engaged in legislative efforts to expand the scope of pharmacy practice or to address disparities in care.** Examples of this may include lobbying at a local, regional, or national level and/or meeting with state or national representatives about pharmacy practice, chemotherapy parity laws, access to care, etc.
2. **Engaged in organizational advocacy through local, regional, or national organizations.** This should preferably include advocacy activities and initiatives through HCT or hematology/oncology organizations such as ASBMT, HOPA, or state-specific oncology/HCT organizations. However, this may also include advocacy activities that a HCT pharmacist has been involved in through other non-oncology organizations such as ASHP, APhA, etc.
3. **Led or participated in research that seeks to promote the value and impact of pharmacists in the care of HCT or hematology/oncology patients.** Examples of this may include, but are not limited to clinical impact on outcomes, pharmacist clinical activity (role), cost savings, revenue generation, improved patient experience, etc. Please be sure to describe the nominees’ role in this research.
4. **Has consistently gone above and beyond in their commitment to outstanding patient care.** Please include a description that includes specific examples of how the nominee has gone above and beyond on a consistent basis for the patients that they serve.

**Please provide any additional information supporting why this candidate should receive the Excellence in Advocacy Award and what unique qualities may separate this candidate from other nominees.**